Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance

Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance

Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapeutics. However, immune-related adverse events (irAEs) increase morbidity and mortality and thereby limit therapeutic utility. The real-world incidence of the entire spectrum of pulmonary irAEs has not been systematic...

Full description

Bibliographic Details
Main Authors: Ugochi Ebinama, Ajay Sheshadri, Kartik Anand, Iyer Swaminathan
Format: Article
Language:English
Published: Innovative Healthcare Institute 2023-11-01
Series:Journal of Immunotherapy and Precision Oncology
Subjects:
ror
pd-1
pd-l1
adverse events
Online Access:https://jipo.org/doi/pdf/10.36401/JIPO-22-38

Internet

https://jipo.org/doi/pdf/10.36401/JIPO-22-38

Similar Items